



Synthesis and biological evaluation of novel disulfides incorporating 1,3,4-thiadiazole scaffold as promising antitumor agents

Sha Li¹ · Hai-Xin Wang¹ · Hai-Ying Liu¹ · Fen Jing¹ · Xiao-Yun Fu¹ · Cai-Wen Li¹ · Yan-Ping Shi¹ · Bao-Quan Chen¹

Received: 18 March 2019 / Accepted: 25 June 2019
© Springer Science+Business Media, LLC, part of Springer Nature 2019

Abstract

In the present study, fourteen 2,5-disubstituted 1,3,4-thiadiazole derivatives containing disulfide group were prepared. The resulting compounds **7a–7n** were identified by IR, NMR, MS, and elemental analysis. Their antiproliferative properties in vitro were studied employing standard CCK-8 assay against SMMC-7721, MCF-7, and A549 lines. Bioassay indicated that some compounds showed stronger antitumor effects than reference drugs PX-12 and 5-fluorouracil. Among these screened compounds, compound **7h** showed excellent biological activities in inhibiting SMMC-7721 cell proliferation with IC₅₀ at 1.93 ± 0.08 μM. Compounds **7k** and **7i** manifested highly effective growth inhibitory activity versus MCF-7 cells, with IC₅₀ at 3.04 ± 0.09 and 3.54 ± 0.17 μM, respectively. For A549 cells, compound **7m** was found to have the highest antitumor potency with IC₅₀ at 3.67 ± 0.13 μM.

Keywords Disulfides · 1,3,4-Thiadiazole · Synthesis · Antitumor activity

Introduction

Malignant tumor is a major disease characterized by abnormal proliferation and metastasis of cells. Its high incidence rate and low survival rate have become one of the greatest threats to human health today. In order to alleviate the suffering of cancer patients, improve the life quality of patients, and prolong the lives of patients, medical scientists from all over the world have made unremitting efforts, but they have not yet fundamentally solved this thorny problem which human face. In recent years, targeted treatment has become an important means of cancer treatment, and has aroused the attention of medical experts around the world. Thioredoxin (Trx) is a kind of multifunctional protein that is

generally expressed in various biological tissues. The Trx system has become a hot spot in the research of tumor molecular biology, and it is a new target of tumor therapy with important clinical significance (Tonissen and Trapani 2009; Lu and Holmgren 2014; Karlén and Tonissen 2010). Over the last decades, there have been several anticancer drugs targeting Trx system in clinical trials (Hashemy et al. 2006; Mehta et al. 2009; Tan et al. 2010). Among them, PX-12 (1-methylpropyl 2-imidazolyl disulfide) is a novel small molecule inhibitor of Trx, which has antitumor effects for a variety of tumor cells. It is also the first disulfide compound which has been reported to enter clinical trials as anticancer drug (Ramanathan et al. 2011; Diraimondo et al. 2013; Baker et al. 2013) (Fig. 1). Therefore, the role of disulfides in the antitumor field has been paid more and more attention (Saiz et al. 2014; Zhu et al. 2015), and this has also stimulated people's interest in the study of disulfide antitumor drugs.

Five-membered heterocyclic compounds, such as 1,3,4-oxadiazoles, 1,3,4-thiadiazoles, and 1,2,4-triazoles, have a very wide range of applications in industry, agriculture, and medicine. In recent years, 1,3,4-thiadiazoles occupies an important position in research and development in the field of medicine, which has aroused widespread interest in the pharmaceutical industry and has conducted a large number of studies owing to their remarkable biological properties, including antitumor (Shi et al. 2013; Bhatt et al. 2018;

Supplementary information The online version of this article (<https://doi.org/10.1007/s00044-019-02389-3>) contains supplementary material, which is available to authorized users.

✉ Cai-Wen Li
lcwlcw66@sina.com
✉ Bao-Quan Chen
chenbaoquan66@126.com

¹ School of Chemistry and Chemical Engineering, Tianjin Key Laboratory of Organic Solar Cells and Photochemical Conversion, Tianjin University of Technology, 300384 Tianjin, China




Fig. 1 Structure of PX-12

Polkam et al. 2015; Rezki et al. 2015), antimicrobial (Shetty et al. 2016; Muçlu et al. 2018), anticholinesterase (Skrzypek et al. 2013; Altintop et al. 2013), antidiabetic (Pattin et al. 2011; Lee et al. 2010), antidepressant (Clerici et al. 2001; Khan et al. 2016), Analgesic (Schenone et al. 2006; Yavuz et al. 2013), anticonvulsant (Luszczki et al. 2015; Karakus et al. 2009), antiinflammatory (Dekhane et al. 2011; Shkair et al. 2016), antimalarial (Huang et al. 2012), antitubercular (Patel et al. 2017), antileishmanial (Alipour et al. 2011; Poorrajab et al. 2009; Foroumadi et al. 2005), antiglaucoma (Casini et al. 2003), and acetylcholinesterase inhibitory properties (Xue et al. 2014). Consequently, people increasingly pay close attention to the development value and potential application prospects of 1,3,4-thiadiazole compounds in the field of medicine. Based on these scientific facts, in order to screen out new antitumor lead compound-bearing disulfide core with high efficiency and low toxicity, hybrid compounds possessing disulfide and 1,3,4-thiadiazole moieties will be formed employing certain chemical means, and some tumor cells growth inhibitory effects will be examined in our research.

Material and methods

Synthesis

All chemical reagents were purchased from Energy Chemical Co. and Tianjin Hengshan Chemical Technology Co., Ltd., and they were used as received from commercial supplies without further purification unless otherwise specified. The bioassay reagents, including RPMI-1640 and PBS, were gotten from Tianjin Jun Yao Biological Technology Co., Ltd. Melting points (m.p., uncorrected) were determined by a X-4 microscope melting point apparatus. Infrared spectra (IR) were obtained in KBr pellets on a Nicolet Avatar 370 spectrometer. Both ^1H NMR and ^{13}C NMR (400 and 100 MHz, respectively) spectra of the synthesized compounds were acquired on a Bruker Avance III 400 MHz spectrometer using $\text{DMSO}-d_6$ as solvent and tetramethylsilane as the internal standard. ESI mass spectra were recorded on a Waters Xevo G2 QToF (ESI) mass spectrometer. Elemental analyses (C, H, N) were performed on a Flash EA1112 analyzer. The reaction progress of some

intermediates, for example **5a–5n** and **6a–6n**, was monitored by thin layer chromatography (TLC).

General method for the synthesis of 2-substituted phenyl-5-substituted disulfanyl-1,3,4-thiadiazoles (**7a–7n**)

To the solution of intermediate **2** and 2-substituted phenyl-5-mercapto-1,3,4-thiadiazoles **6a–6n** (3.0 mmol) in methanol (15 ml) was added the aqueous solution of NaHCO_3 (0.40 g/4.7 mmol in 25 ml water) at ambient temperature with vigorous stirring. The reaction mixture continued to stir for 3 h, then it was cooled at $5\text{--}10^\circ\text{C}$ for 12 h. The precipitated solid was separated, followed by recrystallization from mixture of ethanol and water to yield the desired products.

2-Phenyl-5-(n-butylthio)-1,3,4-thiadiazole (**7a**)

Yellow oil; Yield 60%; IR (cm^{-1}): 3145, 2959, 2939, 2871, 2361, 2342, 1966, 1907, 1694, 1458, 1401, 1281, 1176, 1001, 979, 762, 621, 573; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 7.95 (2H, d, $J = 7.8$ Hz, Ph-H), 7.58 (2H, t, $J = 7.3$ Hz, Ph-H), 7.50 (1H, t, $J = 7.6$ Hz, Ph-H), 3.06 (2H, t, $J = 6.8$ Hz, S-S- CH_2), 1.65–1.72 (2H, m, S-S- CH_2CH_2), 1.36–1.44 (2H, m, CH_2CH_3), 0.88 (3H, t, $J = 7.2$ Hz, CH_3); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ : 168.56, 167.89, 131.75 (2C), 129.69 (2C), 128.77, 127.59, 38.99, 30.95, 21.44, 13.81; MS (ESI, m/z): 283.4 $[\text{M} + \text{H}]^+$; Calculated for $\text{C}_{12}\text{H}_{14}\text{N}_2\text{S}_3$: C, 51.03; H, 5.00; N, 9.92. Found: C, 51.12; H, 4.97; N, 9.97.

2-(4-Aminophenyl)-5-(n-butylthio)-1,3,4-thiadiazole (**7b**)

Yellow solid; m.p.: $73.4\text{--}75.3^\circ\text{C}$; Yield 69%; IR (cm^{-1}): 3132, 2361, 1635, 1401, 1177, 1107, 991, 826, 619; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 7.60 (2H, d, $J = 8.56$ Hz, Ph-H), 6.64 (2H, d, $J = 8.5$ Hz, Ph-H), 5.92 (2H, s, NH_2), 3.02 (2H, t, $J = 7.2$ Hz, S-S- CH_2), 1.64–1.72 (2H, m, S-S- CH_2CH_2), 1.35–1.44 (2H, m, CH_2CH_3), 0.97 (3H, t, $J = 7.2$ Hz, CH_3); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ : 170.75, 168.12, 152.67, 129.47 (2C), 116.73, 114.18 (2C), 38.89, 30.85, 21.34, 13.87; MS (ESI, m/z): 298.5 $[\text{M} + \text{H}]^+$; Calculated for $\text{C}_{12}\text{H}_{15}\text{N}_3\text{S}_3$: C, 48.45; H, 5.08; N, 14.13. Found: C, 48.35; H, 5.11; N, 14.19.

2-(4-Methylphenyl)-5-(n-butylthio)-1,3,4-thiadiazole (**7c**)

Yellow oil; Yield 62%; IR (cm^{-1}): 3145, 2962, 2872, 2360, 2342, 2075, 1635, 1398, 1183, 1120, 1077, 976, 817, 760,

710, 620, 572; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 7.81 (2H, d, $J = 8.0$ Hz, Ph-H), 7.35 (2H, d, $J = 8.0$ Hz, Ph-H), 3.03 (2H, t, $J = 7.2$ Hz, S-S-CH₂), 2.36 (3H, s, Ph-CH₃), 1.61–1.70 (2H, m, S-S-CH₂CH₂), 1.33–1.42 (2H, m, CH₂CH₃), 0.87 (3H, t, $J = 4.4$ Hz, CH₂CH₃); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ : 171.18, 169.92, 142.11, 130.39 (2C), 127.86 (2C), 127.00, 38.86, 30.92, 21.47, 21.36, 13.85; MS (ESI, m/z): 297.5 $[\text{M} + \text{H}]^+$; Calculated for $\text{C}_{13}\text{H}_{16}\text{N}_2\text{S}_3$: C, 52.67; H, 5.44; N, 9.45. Found: C, 52.79; H, 5.47; N, 9.38.

2-(4-Methoxyphenyl)-5-(n-butyldisulfanyl)-1,3,4-thiadiazole (7d)

Yellow solid; m.p.: 55.1–57.0 °C; Yield 73%; IR (cm^{-1}): 3443, 3134, 2360, 2342, 1636, 1401, 1307, 1254, 1131, 1108, 1033, 993, 823, 807, 639, 618; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 7.90 (2H, d, $J = 8.6$ Hz, Ph-H), 7.10 (2H, d, $J = 8.7$ Hz, Ph-H), 3.84 (3H, s, Ph-OCH₃), 3.06 (2H, t, $J = 7.2$ Hz, S-S-CH₂), 1.65–1.73 (2H, m, S-S-CH₂CH₂), 1.35–1.45 (2H, m, CH₂CH₃), 0.87 (3H, t, $J = 7.2$ Hz, CH₂CH₃); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ : 170.59, 169.57, 162.25, 129.63 (2C), 122.29, 115.27 (2C), 55.94, 38.85, 30.89, 21.33, 13.85; MS (ESI, m/z): 313.5 $[\text{M} + \text{H}]^+$; Calculated for $\text{C}_{13}\text{H}_{16}\text{N}_2\text{O}_3\text{S}_3$: C, 49.97; H, 5.16; N, 8.97. Found: C, 50.11; H, 5.13; N 8.92.

2-(3,4,5-Trimethoxyphenyl)-5-(n-butyldisulfanyl)-1,3,4-thiadiazole (7e)

White solid; m.p.: 64.0–66.1 °C; Yield 76%; IR (cm^{-1}): 3447, 3145, 2361, 2343, 2075, 1637, 1509, 1401, 1331, 1192, 1114, 991, 845, 620; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 7.22 (2H, s, Ph-H), 3.88 (6H, s, Ph-OCH₃), 3.74 (3H, s, Ph-OCH₃), 3.07 (2H, t, $J = 7.2$ Hz, S-S-CH₂), 1.67–1.74 (2H, m, S-S-CH₂CH₂), 1.36–1.47 (2H, m, CH₂CH₃), 0.90 (3H, t, $J = 7.6$ Hz, CH₂CH₃); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ : 184.28, 163.35, 153.85 (2C), 140.74, 124.96, 105.29 (2C), 60.61, 56.62 (2C), 38.77, 30.90, 21.33, 13.84; MS (ESI, m/z): 373.5 $[\text{M} + \text{H}]^+$; Calculated for $\text{C}_{15}\text{H}_{20}\text{N}_2\text{O}_3\text{S}_3$: C, 48.36; H, 5.41; N, 7.52. Found: C, 48.26; H, 5.43; N, 7.46.

2-(4-Chlorophenyl)-5-(n-butyldisulfanyl)-1,3,4-thiadiazole (7f)

Yellow solid; m.p.: 37.2–39.1 °C; Yield 77%; IR (cm^{-1}): 3443, 3134, 2361, 2341, 1636, 1401, 1132, 1108, 837, 815, 639, 616, 569; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 7.98 (2H, d, $J = 8.5$ Hz, Ph-H), 7.63 (2H, d, $J = 8.5$ Hz, Ph-H), 3.07 (2H, t, $J = 7.2$ Hz, S-S-CH₂), 1.66–1.73 (2H, m, S-S-CH₂CH₂), 1.34–1.45 (2H, m, CH₂CH₃), 0.90 (3H, t, $J = 7.2$ Hz, CH₂CH₃); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ : 173.93, 167.55, 136.57, 129.86 (2C), 129.44 (2C), 128.54, 38.83, 30.94, 21.37, 13.85; MS (ESI, m/z): 317.4 $[\text{M} + \text{H}]^+$;

Calculated for $\text{C}_{12}\text{H}_{13}\text{ClN}_2\text{S}_3$: C, 45.48; H, 4.13; N, 8.84. Found: C, 45.59; H, 4.10; N 8.89.

2-(4-Nitrophenyl)-5-(n-butyldisulfanyl)-1,3,4-thiadiazole (7g)

Yellow solid; m.p.: 94.2–96.1 °C; Yield 70%; IR (cm^{-1}): 3134, 2360, 2074, 1635, 1517, 1401, 1346, 1107, 991, 864, 853, 752, 687, 619; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 8.38 (2H, d, $J = 8.6$ Hz, Ph-H), 8.24 (2H, d, $J = 8.6$ Hz, Ph-H), 3.10 (2H, t, $J = 7.2$ Hz, S-S-CH₂), 1.67–1.74 (2H, m, S-S-CH₂CH₂), 1.37–1.46 (2H, m, CH₂CH₃), 0.89 (3H, t, $J = 7.2$ Hz, CH₂CH₃); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ : 174.69, 167.45, 149.18, 135.23, 129.16 (2C), 124.93 (2C), 38.76, 30.97, 21.35, 13.85; MS (ESI, m/z): 328.4 $[\text{M} + \text{H}]^+$; Calculated for $\text{C}_{12}\text{H}_{13}\text{N}_3\text{O}_2\text{S}_3$: C, 44.02; H, 4.00; N, 12.83. Found: C, 43.91; H, 3.97; N, 12.90.

2-Phenyl-5-(2-butyldisulfanyl)-1,3,4-thiadiazole (7h)

Yellow oil; Yield 70%; IR (cm^{-1}): 3134, 2968, 2930, 2874, 2360, 2342, 1967 1889, 1636, 1457, 1289, 1108, 1001, 978, 762, 689, 622; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 7.95 (2H, d, $J = 6.7$ Hz, Ph-H), 7.58 (2H, t, $J = 7.1$ Hz, Ph-H), 7.49 (1H, t, $J = 7.2$ Hz, Ph-H), 3.18–3.25 (1H, m, S-S-CH), 1.63–1.75 (1H, m, CH₂-Ha), 1.54–1.63 (1H, m, CH₂-Hb), 1.32 (3H, d, $J = 6.8$ Hz, CH₃CH), 0.95 (3H, t, $J = 7.2$ Hz, CH₂CH₃); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ : 172.51, 169.65, 131.87, 129.81 (2C), 129.75, 127.95 (2C), 49.35, 28.83, 20.10, 11.56; MS (ESI, m/z): 283.4 $[\text{M} + \text{H}]^+$; Calculated for $\text{C}_{12}\text{H}_{14}\text{N}_2\text{S}_3$: C, 51.03; H, 5.00; N, 9.92. Found: C, 51.15; H, 5.05; N, 9.86.

2-(4-Aminophenyl)-5-(2-butyldisulfanyl)-1,3,4-thiadiazole (7i)

Yellow solid; m.p.: 99.4–101.3 °C; Yield 75%; IR (cm^{-1}): 3151, 2074, 1635, 1401, 1107, 994, 823, 617; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 7.61 (2H, d, $J = 8.6$ Hz, Ph-H), 6.64 (2H, d, $J = 8.6$ Hz, Ph-H), 5.92 (2H, s, NH₂), 3.15–3.23 (1H, m, S-S-CH); 1.67–1.76 (1H, m, CH₂-Ha), 1.55–1.66 (1H, m, CH₂-Hb), 1.33 (3H, d, $J = 6.8$ Hz, CH₃CH), 0.95 (3H, t, $J = 7.2$ Hz, CH₂CH₃); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ : 170.93, 168.23, 152.70, 129.51 (2C), 116.67, 114.15 (2C), 49.28, 28.74, 20.14, 11.59; MS (ESI, m/z): 298.5 $[\text{M} + \text{H}]^+$; Calculated for $\text{C}_{12}\text{H}_{15}\text{N}_3\text{S}_3$: C, 48.45; H, 5.08; N, 14.13. Found: C, 48.32; H, 5.13; N, 14.07.

2-(4-Methylphenyl)-5-(2-butyldisulfanyl)-1,3,4-thiadiazole (7j)

Yellow oil; Yield 70%; IR (cm^{-1}): 3134, 2360, 1635, 1507, 1401, 1312, 1289, 1260, 1215, 1183, 1110, 996, 976, 817,

760, 710, 620; ^1H -NMR (400 MHz, $\text{DMSO}-d_6$) δ : 7.83 (2H, d, $J=8.0$ Hz, Ph-H), 7.36 (2H, d, $J=8.0$ Hz, Ph-H), 3.18–3.26 (1H, m, S-S-CH), 2.37 (3H, s, Ph-CH₃), 1.67–1.76 (1H, m, CH₂-Ha), 1.55–1.65 (1H, m, CH₂-Hb), 1.34 (3H, d, $J=6.8$ Hz, CH₃CH), 0.95 (3H, t, $J=7.2$ Hz, CH₂CH₃); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ : 172.24, 169.52, 142.01, 130.38 (2C), 127.84 (2C), 127.07, 49.32, 28.79, 21.47, 20.11, 11.56; MS (ESI, m/z): 297.5 $[\text{M} + \text{H}]^+$; Calculated for $\text{C}_{13}\text{H}_{16}\text{N}_2\text{S}_3$: C, 52.67; H, 5.44; N, 9.45. Found: C, 52.53; H, 5.49; N, 9.39.

2-(4-Methoxyphenyl)-5-(2-butyldisulfanyl)-1,3,4-thiadiazole (7k)

White solid; m.p.: 42.6–44.2 °C; Yield 75%; IR (cm^{-1}): 3145, 2075, 1635, 1401, 1309, 1256, 1109, 992, 837, 811, 620; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 7.90 (2H, d, $J=8.1$ Hz, Ph-H), 7.10 (2H, d, $J=8.0$ Hz, Ph-H), 3.84 (3H, s, Ph-OCH₃), 3.21–3.27 (1H, m, S-S-CH), 1.66–1.73 (1H, m, CH₂-Ha), 1.58–1.65 (1H, m, CH₂-Hb), 1.35 (3H, d, $J=6.4$ Hz, CH₃CH), 0.96 (3H, t, $J=7.2$ Hz, CH₂CH₃); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ : 171.15, 169.59, 162.28, 129.69 (2C), 122.26, 115.30 (2C), 55.97, 49.31, 28.77, 20.13, 11.58; MS (ESI, m/z): 313.5 $[\text{M} + \text{H}]^+$; Calculated for $\text{C}_{13}\text{H}_{16}\text{N}_2\text{O}_3\text{S}_3$: C, 49.97; H, 5.16; N, 8.97. Found: C, 49.82; H, 5.21; N, 8.90.

2-(3,4,5-Trimethoxyphenyl)-5-(2-butyldisulfanyl)-1,3,4-thiadiazole (7l)

Yellow oil; Yield 69%; IR (cm^{-1}): 3135, 2085, 1634, 1586, 1509, 1403, 1330, 1240, 1129, 998, 845, 821, 759, 732, 618; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 7.22 (2H, s, Ph-H), 3.88 (3H, s, Ph-OCH₃), 3.87 (3H, s, Ph-OCH₃), 3.74 (3H, s, Ph-OCH₃), 3.20–3.29 (1H, m, S-S-CH), 1.68–1.78 (1H, m, CH₂-Ha), 1.57–1.67 (1H, m, CH₂-Hb), 1.36 (3H, d, $J=6.8$ Hz, CH₃CH), 0.96 (3H, t, $J=7.6$ Hz, CH₂CH₃); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ : 172.13, 169.62, 153.84 (2C), 140.85 (2C), 124.54, 105.44, 60.60, 56.59 (2C), 49.27, 28.79, 20.01, 11.53; MS (ESI, m/z): 373.5 $[\text{M} + \text{H}]^+$; Calculated for $\text{C}_{15}\text{H}_{20}\text{N}_2\text{O}_3\text{S}_3$: C, 48.36; H, 5.41; N, 7.52. Found: C, 48.48; H, 5.37; N, 7.58.

2-(4-Chlorophenyl)-5-(2-butyldisulfanyl)-1,3,4-thiadiazole (7m)

White solid; m.p.: 52.1–53.9 °C; Yield 72%; IR (cm^{-1}): 3423, 3134, 1634, 1401, 1133, 1108, 996, 851, 821, 639, 615; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 7.99 (d, $J=8.4$ Hz, 2H, Ph-H), 7.63 (2H, d, $J=8.5$ Hz, Ph-H), 3.22–3.30 (1H, m, S-S-CH), 1.69–1.78 (1H, m, CH₂-Ha), 1.57–1.67 (1H, m, CH₂-Hb), 1.36 (3H, d, $J=6.8$ Hz, CH₃CH), 0.97 (3H, t, $J=7.2$ Hz, CH₂CH₃); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ :

166.98, 154.52, 136.65, 129.92 (2C), 129.59 (2C), 128.51, 49.34, 28.81, 20.12, 11.58; MS (ESI, m/z): 317.4 $[\text{M} + \text{H}]^+$; Calculated for $\text{C}_{12}\text{H}_{13}\text{ClN}_2\text{S}_3$: C, 45.48; H, 4.13; N, 8.84. Found: C, 45.40; H, 4.16; N, 8.79.

2-(4-Nitrophenyl)-5-(2-butyldisulfanyl)-1,3,4-thiadiazole (7n)

White solid; m.p.: 114.3–116.5 °C; Yield 74%; IR (cm^{-1}): 3443, 3133, 2359, 1635, 1519, 1401, 1343, 1108, 985, 856, 752, 688, 639, 619; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 8.37 (2H, d, $J=8.0$ Hz, Ph-H), 8.24 (2H, d, $J=7.9$ Hz, Ph-H), 3.26–3.32 (1H, m, S-S-CH), 1.68–1.75 (1H, m, CH₂-Ha), 1.59–1.68 (1H, m, CH₂-Hb), 1.36 (3H, d, $J=6.4$ Hz, CH₃CH), 0.98 (3H, t, $J=7.2$ Hz, CH₂CH₃); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ : 175.41, 167.38, 149.23, 135.27, 129.22 (2C), 124.96 (2C), 49.39, 28.84, 20.13, 11.59; MS (ESI, m/z): 328.4 $[\text{M} + \text{H}]^+$; calculated for $\text{C}_{12}\text{H}_{13}\text{N}_3\text{O}_2\text{S}_3$: C, 44.02; H, 4.00; N, 12.83. Found: C, 44.11; H, 4.04; N, 12.78.

Tumor cell growth inhibitory assay

The cell lines (SMMC-7721, MCF-7, and A549) were cultured in proper medium in a 5% CO_2 at 37 °C during the experiment. The inhibition (IC_{50}) of the selected tumor cells proliferation by target compounds **7a–7n** and reference drugs was measured by our previous method as described in literature (Wang et al. 2017).


Results and discussion

Synthesis

The synthesis pathway of 2-substituted phenyl-5-substituted disulfanyl-1,3,4-thiadiazoles **7a–7n** is shown in Scheme 1, all of the fourteen 1,3,4-thiadiazole derivatives are unknown compounds. The reaction of thiourea and *n*-butylthiol, 2-butythiol yielded S-alkyl-thioisothiurea hydrochloride **2** following the literature method (Sirakawa et al. 1970), which was directly used for the next step reaction without being purified. The synthesis of 2-substituted phenyl-5-mercapto-1,3,4-thiadiazoles **6a–6n** was commenced with benzoic acid by four steps in total yield 45.1–65.0% (Jha et al. 2010; Li et al. 2013). First, condensation of appropriate benzoic acid **3a–3n** with ethanol gave ester **4a–4n** (79.3–88.4%). Hydrazidation of ester **4a–4n** delivered the benzohydrazide **5a–5n** (80.1–91.4%), which reacted with CS_2 and KOH produced compounds **6a–6n** (71.0–80.5%). Finally, nucleophilic replacement of **6a–6n** with **2** in the presence of NaHCO_3 yielded 2-substituted phenyl-5-substituted disulfanyl-1,3,4-thiadiazoles **7a–7n** in moderate

Scheme 1 Synthetic pathway of the title compounds **7a–7n**.

Reaction conditions and reagents: **a** Concd. HCl, H₂O₂ (30%), 0–5 °C, 3 h; **b** EtOH, concd. H₂SO₄, reflux, 8–12 h; **c** NH₂NH₂·H₂O, EtOH, reflux, 5–8 h; **d** (i) KOH, CS₂, EtOH, 0–5 °C, 2 h; (ii) Concd. H₂SO₄, 0–5 °C, 2 h; **e** Compound **2**, MeOH, NaHCO₃/H₂O, rt, 3 h



R₂ (R₁ = *n*-C₄H₉): H (**7a**), 4-NH₂ (**7b**), 4-CH₃ (**7c**), 4-OCH₃ (**7d**), 3, 4, 5-(OCH₃)₃ (**7e**), 4-Cl (**7f**), 4-NO₂ (**7g**); R₂ (R₁ = 2-C₄H₉): H (**7h**), 4-NH₂ (**7i**), 4-CH₃ (**7j**), 4-OCH₃ (**7k**), 3, 4, 5-(OCH₃)₃ (**7l**), 4-Cl (**7m**), 4-NO₂ (**7n**)

yields. The pure form of the compounds **7a–7n** was obtained by recrystallization from the mixture of ethanol and water.

Pharmacology evaluation

The title compounds consist of two series, which were known as **7a–7g** and **7h–7n**, respectively. Compounds **7a–7g** all possess a *n*-butyl group linked with disulfide bond, whereas, compounds **7h–7n** all carry 2-butyl group bonded to disulfide. Evaluation of the antitumor activity in vitro for 2-substituted phenyl-5-substituted disulfany-1,3,4-thiadiazoles **7a–7n** was carried out by utilizing CCK-8 assay versus three types of tumor cell lines, namely, SMMC-7721, MCF-7, and A549. The inhibitory activities IC₅₀ (μM) are shown in Table 1.

We found from the results that all tested compounds **7a–7n** displayed admissible antiproliferative activities for selected tumor cell lines. For SMMC-7721 cells, **7m** showed moderate antitumor effect (IC₅₀ = 17.83 ± 0.68 μM), whereas, the rest of tested compounds exhibited good inhibitory efficacy (IC₅₀ = 1.93–8.60 μM). Meanwhile, most title compounds were found to possess higher antiproliferative activity in comparison with 5-fluorouracil (IC₅₀ = 5.62 ± 0.28 μM). Among them, six compounds, including **7d**, **7e**, **7h**, **7i**, **7j**, and **7l** revealed higher antitumor effect than PX-12 (IC₅₀ = 4.05 ± 0.32 μM). By

Table 1 Inhibition (IC₅₀) of SMMC-7721, MCF-7, and A549 cells proliferation by compounds **7a–7n**

| Compound | IC ₅₀ (μM) | | |
|--------------|-----------------------|--------------|--------------|
| | SMMC-7721 | MCF-7 | A549 |
| 7a | 4.64 ± 0.18 | 8.60 ± 0.38 | 32.77 ± 1.98 |
| 7b | 8.60 ± 0.33 | 25.95 ± 1.47 | 7.80 ± 0.33 |
| 7c | 4.39 ± 0.11 | 9.66 ± 0.45 | 9.85 ± 0.42 |
| 7d | 2.94 ± 0.09 | 8.00 ± 0.37 | 6.95 ± 0.22 |
| 7e | 2.28 ± 0.12 | 7.80 ± 0.12 | 33.37 ± 2.17 |
| 7f | 7.90 ± 0.32 | 6.74 ± 0.31 | 8.80 ± 0.29 |
| 7g | 5.14 ± 0.24 | 8.20 ± 0.33 | 14.37 ± 0.56 |
| 7h | 1.93 ± 0.08 | 8.20 ± 0.21 | 18.73 ± 0.51 |
| 7i | 3.69 ± 0.26 | 3.54 ± 0.17 | 8.00 ± 0.18 |
| 7j | 3.89 ± 0.15 | 4.49 ± 0.16 | 6.35 ± 0.39 |
| 7k | 6.15 ± 0.31 | 3.04 ± 0.09 | 33.37 ± 1.88 |
| 7l | 2.94 ± 0.13 | 8.25 ± 0.25 | 5.89 ± 0.24 |
| 7m | 17.83 ± 0.68 | 6.35 ± 0.18 | 3.67 ± 0.13 |
| 7n | 6.89 ± 0.29 | 9.10 ± 0.40 | 35.63 ± 2.28 |
| PX-12 | 4.05 ± 0.32 | 5.12 ± 0.21 | 10.51 ± 0.30 |
| 5-FU | 5.62 ± 0.28 | 14.26 ± 0.66 | 8.13 ± 0.34 |

comparing **7a** with **7h**, although they have the same phenyl substituent in position 2 of 1,3,4-thiadiazole, we found that the difference is obvious in their antitumor efficacy. Compound **7h** having 2-butyl group linked to disulfide, showed

better activity than **7a**. Similarly, **7b** and **7i**, **7d** and **7k**, **7f** and **7m** also emerged obvious differences in antitumor potency. Especially noteworthy is compound **7h** displayed excellent growth inhibitory activity ($IC_{50} = 1.93 \pm 0.08 \mu M$). We also found substitutes at phenyl ring, have obvious effects on biological activity, but further research and discussion are needed. For MCF-7 cells, compound **7b** carrying 4-amino group at the phenyl ring, showed moderate antiproliferative activity ($IC_{50} = 25.95 \pm 1.47 \mu M$). The other screened compounds emerged good cytotoxic efficacy ($IC_{50} < 10 \mu M$), and displayed higher activities than 5-fluorouracil ($IC_{50} = 14.26 \pm 0.66 \mu M$). But most compounds did not show obvious advantage in comparison with PX-12 ($IC_{50} = 5.12 \pm 0.21 \mu M$). **7a** and **7h**, **7e** and **7l**, **7f** and **7m**, **7g** and **7n** showed similar activity against MCF-7 cells, respectively. but **7b** and **7i**, **7c** and **7j**, **7d** and **7k** revealed obvious differences in antitumor potency, respectively. Compounds **7k** and **7i** were manifested promising growth inhibitory activity with IC_{50} at 3.04 ± 0.09 and $3.54 \pm 0.17 \mu M$, respectively. **7i**, **7j**, **7k**, and **7l** carrying electron-donating groups, including 4-amino, 4-methyl, 4-methoxy and 3,4,5-trimethoxy, respectively, were superior to **7h** in antitumor efficacy. For A549 cells, six compounds, including **7a**, **7e**, **7g**, **7h**, **7k**, and **7n** revealed moderate antiproliferative activities ($IC_{50} = 14.37$ – $35.63 \mu M$), whereas, the rest of compounds displayed good potency ($IC_{50} = 3.67$ – $9.85 \mu M$), and some compounds showed higher effects than PX-12 ($IC_{50} = 10.51 \pm 0.30 \mu M$) and 5-fluorouracil ($IC_{50} = 8.13 \pm 0.34 \mu M$). Especially, 4-chloro-substituted derivative, compound **7m** was found to have the strongest cytotoxic efficacy ($IC_{50} = 3.67 \pm 0.13 \mu M$). Except **7e** ($IC_{50} = 35.63 \pm 2.28 \mu M$), the other compounds carrying various substituents all showed highly enhanced potency against A549 cells compared to compound **7a**. In addition, we found that the tested compounds displayed preferential growth inhibitory activity to SMMC-7721 compared to A549 cells on the whole. Therefore, we believe that the above findings are useful for further studies on structure–activity relationship.

Conclusion

The present work comprises the synthesis of some new 2-substituted phenyl-5-substituted disulfany-1,3,4-thiadiazoles **7a**–**7n** and screening for their antitumor activities against SMMC-7721, MCF-7, and A549 lines via CCK-8 assay. Our preliminary investigation revealed that the tested compounds have potency of inhibition for three tumor cell lines, and the effects of substituents on anticancer efficacy have been observed. Interestingly, some compounds showed stronger antitumor effects than reference drugs PX-12 and 5-fluorouracil, and several screened compounds,

such as **7h**, **7i**, **7k**, and **7m** displayed promising biological activities. Therefore, the pharmacological results could be helpful for the development of new anticancer agents.

Acknowledgements This study was financially supported by Tianjin Municipal Natural Science Foundation (18JCYBJC94900), and Training Project of Innovation Team of Colleges and Universities in Tianjin (TD13-5020). The authors greatly thank Prof. Y.M. Liu for his help in confirming the structure of the newly synthesized compounds, and we also thank Dr. W. Li for her help in evaluating antitumor activity of the screened compounds.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

- Alipour E, Emami S, Yahya-Meymand A, Nakhjiri M, Johari F, Ardestani SK, Poorrajab F, Hosseini M, Shafiee A, Foroumadi A (2011) Synthesis and antileishmanial activity of 5-(5-nitroaryl)-2-substituted-thio-1,3,4-thiadiazoles. *J Enzyme Inhib Med Chem* 26:123–128
- Altintop MD, Kaplancikli ZA, Ozdemir A, Turan-Zitouni G, Temel HE, Akalin G (2012) Synthesis and anticholinesterase activity and cytotoxicity of novel amide derivatives. *Arch Pharm Chem Life Sci* 345:112–116
- Baker AF, Adab KN, Raghunand N, Chow HHS, Stratton SP, Squire SW, Boice M, Pestano LA, Kirkpatrick DL, Dragovich T (2013) A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, inpatients with advanced gastrointestinal cancers. *Invest New Drugs* 31:631–641
- Bhatt P, Kumar M, Jha A (2018) Synthesis, docking and anticancer activity of azo-linked hybrids of 1,3,4-thia-oxadiazoles with cyclic imides. *Mol Divers* 22:827–840
- Casini A, Scozzafava A, Mincione F, Menabuoni L, Starnotti M, Supuran CT (2003) Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzamide. *Bioorg Med Chem Lett* 13:2867–2873
- Clerici F, Pocar D, Guido M, Loche A, Perlini V, Brufani M (2001) Synthesis of 2-amino-5-sulfany-1,3,4-thiadiazole derivatives and evaluation of their antidepressant and anxiolytic activity. *J Med Chem* 44:931–936
- Dekhane DV, Pawar SS, Gupta S, Shingare MS, Patil CR, Thore SN (2011) Synthesis and anti-inflammatory activity of some new 4,5-dihydro-1,5-diaryl-1H-pyrazole-3-substituted-heteroazole derivatives. *Bioorg Med Chem Lett* 21:6527–6532
- Diraimondo TR, Plugis NM, Jin X, Khosla C (2013) Selective inhibition of extracellular thioredoxin by asymmetric disulfides. *J Med Chem* 56:1301–1310
- Foroumadi A, Pournourmohammadi S, Soltani F, Asgharian-Rezaee M, Dabiri S, Kharazmi A, Shafiee A (2005) Synthesis and in vitro leishmanicidal activity of 2-(5-nitro-2-furyl) and 2-(5-nitro-2-thienyl)-5-substituted-1,3,4-thiadiazoles. *Bioorg Med Chem Lett* 15:1983–1985
- Hashemy SL, Ungerstedt JS, Avval FZ, Holmgren A (2006) Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. *J Biol Chem* 281:10691–10697

- Huang H, Lu WQ, Li X, Cong XL, Ma HM, Liu XF, Zhang Y, Che P, Ma RQ, Li HL, Shen X, Jiang HL, Huang J, Zhu J (2012) Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent. *Bioorg Med Chem Lett* 22:958–962
- Jha KK, Samad A, Kumar Y, Shaharyar M, Khosa RL, Jain J, Kumar V, Singh P (2010) Design, synthesis and biological evaluation of 1,3,4-oxadiazole derivatives. *Eur J Med Chem* 45:4963–4967
- Karakus S, Koçyiğit-Kaymakcioğlu B, Toklu HZ, Aricioglu F, Rollas S (2009) Synthesis and anticonvulsant activity of new N-(alkyl/substitutedaryl)-N'-[4-(5-cyclohexylamino)-1,3,4-thiadiazole-2-yl]phenylthioureas. *Arch Pharm Chem Life Sci* 342:48–53
- Karlenius TC, Tonissen KF (2010) Thioredoxin and cancer: a role for thioredoxin in all states of tumor oxygenation. *Cancers* 2:209–232
- Khan I, Tantray MA, Hamid H, Alam MS, Kalam A, Dhulap A (2016) Synthesis of benzimidazole based thiadiazole and carbohydrazide conjugates as glycogen synthase kinase-3b inhibitors with antidepressant activity. *Bioorg Med Chem Lett* 26:4020–4024
- Lee J, Lee SH, Seo HJ, Son EJ, Lee SH, Jung ME, Lee MW, Han HK, Kim J, Kang J, Lee J (2010) Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-thiadiazolylmethylphenyl glucoside congeners. *Bioorg Med Chem* 18:2178–2194
- Li P, Yin J, Xu WM, Wu J, He M, Hu DY, Yang S, Song BA (2013) Synthesis, antibacterial activities, and 3D-QSAR of sulfone derivatives containing 1,3,4-oxadiazole moiety. *Chem Biol Drug Des* 82:546–556
- Lu J, Holmgren A (2014) The thioredoxin antioxidant system. *Free Radic Biol Med* 66:75–87
- Luszczki JJ, Karpińska M, Matysiak J, Niewiadomy J (2015) Characterization and preliminary anticonvulsant assessment of some 1,3,4-thiadiazole derivatives. *Pharmacol Rep* 67:588–592
- Mehta MP, Shapiro WR, Phan SC, Gervais R, Carrie C, Chabot P, Patchell RA, Glantz MJ, Recht L, Langer C, Sur RK, Roa WH, Mahe MA, Fortin A, Nieder C, Meyers CA, Smith JA, Miller RA, Renschler MF (2009) Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. *Int J Radiat Oncol Biol Phys* 73:1069–1076
- Muğlu H, Şener N, Emsaed HAM, Özkınalı S, Özkan OE, Gür M (2018) Synthesis and characterization of 1,3,4-thiadiazole compounds derived from 4-phenoxybutyric acid for antimicrobial activities. *J Mol Struct* 1174:151–159
- Patel HM, Noolvi MN, Sethi NS, Gadad AK, Cameotra SS (2017) Synthesis and antitubercular evaluation of imidazo [2,1-b] [1,3,4] thiadiazole derivatives. *Arab J Chem* 10:S996–S1002
- Pattn SR, Kittur BS, Sastry BS, Jadav SG, Thakur DK, Madamwar SA, Shinde HV (2011) Synthesis and evaluation of some novel 1,3,4-thiadiazoles for antidiabetic activity. *Indian J Chem* 50B:615–618
- Polkam N, Rayam P, Anireddy JS, Yennam S, Anantaraju HS, Dharmarajan S, Perumal Y, Kotapalli SS, Ummanni R, Balasubramanian S (2015) Synthesis, in vitro anticancer and antimycobacterial evaluation of new 5-(2,5-dimethoxyphenyl)-1,3,4-thiadiazole-2-amino derivatives. *Bioorg Med Chem Lett* 25:1398–1402
- Poorrajab F, Ardestani SK, Emami S, Behrouzi-Fardmoghdam M, Shafiee A, Foroumadi A (2009) Nitroimidazolyl-1,3,4-thiadiazole-based anti-leishmanial agents: synthesis and in vitro biological evaluation. *Eur J Med Chem* 44:1758–1762
- Ramanathan RK, Abbruzzese J, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, Pestano LA, Green S, Von Hoff DD (2011) A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. *Cancer Chemother Pharmacol* 67:503–509
- Rezki N, Al-Yahyawi AM, Bardaweel SK, Al-Blewi FF, Aouad MR (2015) Synthesis of novel 2,5-disubstituted-1,3,4-thiadiazoles clubbed 1,2,4-triazole, 1,3,4-thiadiazole, 1,3,4-oxadiazole and/or schiff base as potential antimicrobial and antiproliferative agents. *Molecules* 20:16048–16067
- Saiz C, Castillo V, Fontán P, Bonilla M, Salinas G, Rodríguez-Haralambides A, Mahler SG (2014) Discovering echinococcus granulosis thioredoxin glutathione reductase inhibitors through site-specific dynamic combinatorial chemistry. *Mol Divers* 18:1–12
- Schenone S, Brullo C, Bruno O, Bondavalli F, Ranise A, Filippelli W, Rinaldi B, Capuano A, Falcone G (2006) New 1,3,4-thiadiazole derivatives endowed with analgesic and anti-inflammatory activities. *Bioorg Med Chem* 14:1698–1705
- Shetty P, Praveen BM, Raghavendra M, Manjunath K, Cheruku S (2016) Synthesis and antimicrobial evaluation of novel 4-amino-6-(1,3,4-oxadiazolo/1,3,4-thiadiazolo)-pyrimidine derivatives. *Mol Divers* 20:391–398
- Shi YJ, Song XJ, Li X, Ye TH, Xiong Y, Yu LT (2013) Synthesis and biological evaluation of 1,2,4-triazole and 1,3,4-thiadiazole derivatives as potential cytotoxic agents. *Chem Pharm Bull* 61:1099–1104
- Shkair AMH, Shakya AK, Raghavendra NM, Naik RR (2016) Molecular modeling, Synthesis and pharmacological evaluation of 1,3,4-thiadiazoles as anti-inflammatory and analgesic agents. *Med Chem* 12:90–100
- Sirakawa K, Aki O, Tsujikawa T (1970) S-alkylthioisothioureas. I. *Chem Pharm Bull* 18:235–242
- Skrzypek A, Matysiak J, Karpińska MM, Niewiadomy A (2013) Synthesis and anticholinesterase activities of novel 1,3,4-thiadiazole based compounds. *J Enzym Inhib Med Chem* 28:816–823
- Tan Q, Li J, Yin HW, Wang LH, Tang WC, Zhao F, Liu XM, Zeng HH (2010) Augmented antitumor effects of combination therapy of cisplatin with etaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo. *Invest New Drugs* 28:205–215
- Tonissen KF, Trapani GD (2009) Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. *Mol Nutr Food Res* 53:87–103
- Wang XF, Zhang S, Li BL, Zhao JJ, Liu YM, Zhang RL, Li B, Chen BQ (2017) Synthesis and biological evaluation of disulfides bearing 1,2,4-triazole moiety as antiproliferative agents. *Med Chem Res* 26:3367–3374
- Xue XJ, Wang YB, Lu P, Shang HF, She JX, Xia LX, Qian H, Huang WL (2014) Synthesis and in vitro evaluation of 1,3,4-thiadiazol-2-yl urea derivatives as novel AChE inhibitors. *Chem Pharm Bull* 62:524–527
- Yavuz S, Ünal Y, Pamir Ö, Yilmazer D, Kurtipek Ö, Kavutçu M, Arslan M, Ark M, Yıldırım Y (2013) Synthesis and pharmacological evaluation of some novel thebaine derivatives: N-(tetrazol-1H-5-yl)-6,14-endoethenotetrahydrothebaine incorporating the 1,3,4-oxadiazole or the 1,3,4-thiadiazole moiety. *Arch Pharm Chem Life Sci* 346:455–462
- Zhu SJ, Ying HZ, Wu Y, Qiu N, Liu T, Yang B, Dong XW, Hu YZ (2015) Design, synthesis and biological evaluation of novel podophyllotoxin derivatives bearing 4β-disulfide/trisulfide bond as cytotoxic agents. *RSC Adv* 5:103172–103183